Table 2 Time-averaged analysis: mean changes from baseline
Endpoint | Parameter | Placebo (N = 50) | NEPA200/0.5(N = 48) | NEPA600/1.5(N = 49) | Moxifloxacin (N = 49) | |||
|---|---|---|---|---|---|---|---|---|
Change from baseline | Change from baseline | Placebo-corrected change from baseline | Change from baseline | Placebo-corrected change from baseline | Change from baseline | Placebo-corrected change from baseline | ||
Primary | QTcI, ms | –2.1 | 2.6 | 4.7 | 1.5 | 3.6 | 6.3 | 8.4 |
|  | (Min;max) | (−8.3; 4.8) | (−5.8; 30.6) |  | (−7.3; 14.3) |  | (−2.6; 15.3) |  |
Secondary | HR, bpm | –0.7 | –4.0 | –3.3 | –3.7 | –3.0 | –0.4 | 0.3 |
|  | PR, ms | 1.1 | 0.7 | –0.4 | 1.3 | 0.2 | –0.2 | –1.3 |
|  | QRS, ms | –0.3 | 0.7 | 1.0 | 0.2 | 0.5 | 0.0 | 0.3 |
|  | QT, ms | –0.4 | 9.3 | 9.7 | 8.6 | 9.0 | 6.9 | 7.3 |
|  | QTcF, ms | –2.1 | 0.5 | 2.6 | 0.5 | 2.6 | 6.0 | 8.1 |
|  | QTcB, ms | –3.0 | –3.9 | –0.9 | –3.5 | –0.5 | 5.5 | 8.5 |